Arete Wealth Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Arete Wealth Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-39,544	Closed	-$193K	–	676
2025 Q3	$193K	Sell	39,544 -50,900	-56%	-$267K	0.01%	731
2025 Q2	$458K	Buy	90,444 +77,650	+607%	+$381K	0.03%	433
2025 Q1	$68K	Buy	12,794 +1,138	+10%	+$8.3K	0.01%	699
2024 Q4	$78K	Hold	11,656	–	–	0.01%	725
2024 Q3	$77K	Buy	+11,656	New	+$83.6K	0.01%	683

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Arete Wealth Advisors's RXRX Position: Q4 2025 in Review

Arete Wealth Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 39,544 shares — an estimated $193K sold.

Arete Wealth Advisors first reported a position in RXRX in Q3 2024 and held it in 5 quarters. The position peaked at $458K in Q2 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Arete Wealth Advisors reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Arete Wealth Advisors sold 39,544 Recursion Pharmaceuticals shares in Q4 2025, an estimated $193K.
Arete Wealth Advisors first reported a position in Recursion Pharmaceuticals in Q3 2024 and held it in 5 quarters.
Arete Wealth Advisors's Recursion Pharmaceuticals position peaked at $458K in Q2 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Arete Wealth Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.